BRD-K98762074-001-01-2 (Substance)

Compound:

(E)-N-(4-((4-Ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl)vinyl)-4-methylbenzamide

Compound (Entity type)

Synonyms:BRD-K98762074-001-01-2

Id:177749456

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View BRD-K98762074-001-01-2's neighborhood in the knowledge graph.

Submit

Results found

Linked to

	Label	Description
	L1000 LINCS DCIC LJP006 HME1 3H M03 HG-6-64-01 1.11um Biosample (Entity type)	A biosample from LINCS produced as part of the L1000 Phase2 project
	L1000 LINCS DCIC 2021 LJP006 MCF10A 24H M06 HG-6-64-01 0.04uM Biosample (Entity type)	A biosample from LINCS produced as part of the LINCS 2021 project
	L1000 LINCS DCIC LJP006 HME1 3H M02 HG-6-64-01 3.33um Biosample (Entity type)	A biosample from LINCS produced as part of the L1000 Phase2 project
	L1000 LINCS DCIC LJP006 A375 24H M01 HG-6-64-01 10.00um Biosample (Entity type)	A biosample from LINCS produced as part of the L1000 Phase2 project
	L1000 LINCS DCIC LJP006 A549 24H M02 HG-6-64-01 3.33um Biosample (Entity type)	A biosample from LINCS produced as part of the L1000 Phase2 project
	L1000 LINCS DCIC 2021 LJP006 HS578T 3H M04 HG-6-64-01 0.37uM Biosample (Entity type)	A biosample from LINCS produced as part of the LINCS 2021 project
	L1000 LINCS DCIC 2021 LJP006 LNCAP 24H M04 HG-6-64-01 0.37uM Biosample (Entity type)	A biosample from LINCS produced as part of the LINCS 2021 project
	L1000 LINCS DCIC 2021 LJP006 LNCAP 24H M03 HG-6-64-01 1.11uM Biosample (Entity type)	A biosample from LINCS produced as part of the LINCS 2021 project
	L1000 LINCS DCIC 2021 LJP006 MCF7 3H M01 HG-6-64-01 10uM Biosample (Entity type)	A biosample from LINCS produced as part of the LINCS 2021 project
	L1000 LINCS DCIC LJP001 HS578T 24H C14 HG-6-64-01 2.00um Biosample (Entity type)	A biosample from LINCS produced as part of the L1000 Phase1 project

L1000 LINCS DCIC LJP006 HME1 3H M03 HG-6-64-01 1.11um

Biosample (Entity type)

A biosample from LINCS produced as part of the L1000 Phase2 project

L1000 LINCS DCIC 2021 LJP006 MCF10A 24H M06 HG-6-64-01 0.04uM

Biosample (Entity type)

A biosample from LINCS produced as part of the LINCS 2021 project

L1000 LINCS DCIC LJP006 HME1 3H M02 HG-6-64-01 3.33um

Biosample (Entity type)

A biosample from LINCS produced as part of the L1000 Phase2 project

L1000 LINCS DCIC LJP006 A375 24H M01 HG-6-64-01 10.00um

Biosample (Entity type)

A biosample from LINCS produced as part of the L1000 Phase2 project

L1000 LINCS DCIC LJP006 A549 24H M02 HG-6-64-01 3.33um

Biosample (Entity type)

A biosample from LINCS produced as part of the L1000 Phase2 project

L1000 LINCS DCIC 2021 LJP006 HS578T 3H M04 HG-6-64-01 0.37uM

Biosample (Entity type)

A biosample from LINCS produced as part of the LINCS 2021 project

L1000 LINCS DCIC 2021 LJP006 LNCAP 24H M04 HG-6-64-01 0.37uM

Biosample (Entity type)

A biosample from LINCS produced as part of the LINCS 2021 project

L1000 LINCS DCIC 2021 LJP006 LNCAP 24H M03 HG-6-64-01 1.11uM

Biosample (Entity type)

A biosample from LINCS produced as part of the LINCS 2021 project

L1000 LINCS DCIC 2021 LJP006 MCF7 3H M01 HG-6-64-01 10uM

Biosample (Entity type)

A biosample from LINCS produced as part of the LINCS 2021 project

L1000 LINCS DCIC LJP001 HS578T 24H C14 HG-6-64-01 2.00um

Biosample (Entity type)

A biosample from LINCS produced as part of the L1000 Phase1 project

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.